A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel, Niral; Mishra, Vishal; Patel, Prakruti; Dikshit, R K

doi:10.1186/2251-6581-13-62

Cited by 21 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the analgesic action of pregabalin is also proposed to be the result of impaired trafficking of α2δ1 subunit with a consequent diminished expression of functional calcium channels [133] . Several clinical trials evaluating pregabalin in DNP showed efficacy in the management of this condition [3,134,135] with a number needed to treat (NNT) of 6.3 [125] .…”

Section: Anticonvulsantsmentioning

confidence: 99%

“…In addition to its analgesic effects, pregabalin presents anxiolytic activity [132,135] and it has a beneficial effect on sleep and quality of life [132] , contributing, therefore, to improve the general condition of the patients. The side effects include dizziness, somnolence, peripheral edema, headache and weight gain [3] .…”

Section: Anticonvulsantsmentioning

confidence: 99%

“…Alpha lipoic acid: The benefit provided by alpha lipoic acid (ALA) in the treatment of DNP possibly is due to its direct effects on the neuropathy, by reducing the oxidative stress, which has been defined as an important factor in the physiopatology of the diabetic neuropathy [122] . Its antioxidant and antiinflammatory actions may contribute to an allround improvement of diabetic neuropathy symptoms [135] . In some clinical trials that evaluated ALA effect in diabetic patients, pain was not a primary end point.…”

Section: Others Agentsmentioning

confidence: 99%

See 2 more Smart Citations

Diabetic neuropathic pain: Physiopathology and treatment

Schreiber

Nones

Reis

et al. 2015

WJD

355

267

View full text Add to dashboard Cite

Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes, which affects over 90% of the diabetic patients. Although pain is one of the main symptoms of diabetic neuropathy, its pathophysiological mechanisms are not yet fully known. It is widely accepted that the toxic effects of hyperglycemia play an important role in the development of this complication, but several other hypotheses have been postulated. The management of diabetic neuropathic pain consists basically in excluding other causes of painful peripheral neuropathy, improving glycemic control as a prophylactic therapy and using medications to alleviate pain. First line drugs for pain relief include anticonvulsants, such as pregabalin and gabapentin and antidepressants, especially those that act to inhibit the reuptake of serotonin and noradrenaline. In addition, there is experimental and clinical evidence that opioids can be helpful in pain control, mainly if associated with first line drugs. Other agents, including for topical application, such as capsaicin cream and lidocaine patches, have also been proposed to be useful as adjuvants in the control of diabetic neuropathic pain, but the clinical evidence is insufficient to support their use. In conclusion, a better understanding of the mechanisms underlying diabetic neuropathic pain will contribute to the search of new therapies, but also to the improvement of the guidelines to optimize pain control with the drugs currently available.

show abstract

Section: Anticonvulsantsmentioning

confidence: 99%

Section: Anticonvulsantsmentioning

confidence: 99%

Section: Others Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Diabetic neuropathic pain: Physiopathology and treatment

Schreiber

Nones

Reis

et al. 2015

WJD

355

267

View full text Add to dashboard Cite

show abstract

“…Another prospective, observational study showed that after 21 months patients using pregabalin had better improvement in symptoms of diabetic neuropathy in comparison to patients using either carbamazepine and ALA [164] . …”

Section: Clinical Use Of Ala In Diabetesmentioning

confidence: 99%

Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

Gomes

Negrato²

2014

Diabetol Metab Syndr

233

164

View full text Add to dashboard Cite

Alpha-lipoic acid is a naturally occurring substance, essential for the function of different enzymes that take part in mitochondria’s oxidative metabolism. It is believed that alpha-lipoic acid or its reduced form, dihydrolipoic acid have many biochemical functions acting as biological antioxidants, as metal chelators, reducers of the oxidized forms of other antioxidant agents such as vitamin C and E, and modulator of the signaling transduction of several pathways. These above-mentioned actions have been shown in experimental studies emphasizing the use of alpha-lipoic acid as a potential therapeutic agent for many chronic diseases with great epidemiological as well economic and social impact such as brain diseases and cognitive dysfunctions like Alzheimer disease, obesity, nonalcoholic fatty liver disease, burning mouth syndrome, cardiovascular disease, hypertension, some types of cancer, glaucoma and osteoporosis. Many conflicting data have been found concerning the clinical use of alpha-lipoic acid in the treatment of diabetes and of diabetes-related chronic complications such as retinopathy, nephropathy, neuropathy, wound healing and diabetic cardiovascular autonomic neuropathy. The most frequent clinical condition in which alpha-lipoic acid has been studied was in the management of diabetic peripheral neuropathy in patients with type 1 as well type 2 diabetes. Considering that oxidative stress, a imbalance between pro and antioxidants with excessive production of reactive oxygen species, is a factor in the development of many diseases and that alpha-lipoic acid, a natural thiol antioxidant, has been shown to have beneficial effects on oxidative stress parameters in various tissues we wrote this article in order to make an up-to-date review of current thinking regarding alpha-lipoic acid and its use as an antioxidant drug therapy for a myriad of diseases that could have potential benefits from its use.Electronic supplementary materialThe online version of this article (doi:10.1186/1758-5996-6-80) contains supplementary material, which is available to authorized users.

show abstract

“…LA, a powerful antioxidant, can inhibit the generation of oxygen free radicals and thus can regulate GSH. This suggested that LA might have certain protective effects against diseases induced by oxygen free radicals (Bhadri et al, 2013;Guo et al, 2014;Patel et al, 2014). Our study demonstrated that Aβ peptides could significantly inhibit the proliferation of C6 cells, while LA could reverse the inhibition effect of Aβ and promote the recovery of cell viability.…”

Section: Discussionmentioning

confidence: 62%

Effects and mechanism of lipoic acid on beta-amyloid-intoxicated C6 glioma cells

Xing

Qin

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. β-amyloid peptides (Aβs) can exert neurotoxic effects through induction of oxidative damage, whereas lipoic acid (LA), a powerful antioxidant, can alleviate oxidative damage. In this study, we explored the effect and mechanism of action of LA on beta-amyloidintoxicated C6 glioma cells. Cells were randomly divided into three groups: control (vehicle), Aβ, and LA + Aβ. The LA + Aβ group was treated with LA for 2 h, then both the Aβ-only and the LA + Aβ groups were incubated with 25 μM Aβ for 24 h. Cell viability was measured by the MTT method. Mitochondrial reduced glutathione (GSH) and oxidized glutathione (GSSG) levels were detected by enzyme-linked immunosorbent assay (ELISA), and the GSH to GSSG ratio calculated. Real-time polymerase chain reaction and western blot analyses were used to detect MnSOD mRNA and protein, respectively. Aβ significantly inhibited C6 cell proliferation compared with the control group (P < 0.05). LA markedly increased cell viability compared with the Aβ group (P < 0.05). The increased GSSH and decreased GSH mitochondrial accumulation induced by Aβ was profoundly reversed by treatment with LA (P < 0.05). Aβ significantly reduced MnSOD expression compared to controls (P < 0.05), whereas LA pretreatment increased MnSOD expression compared with the Aβ-only group (P < 0.05); MnSOD protein levels showed similar patterns. These results suggest that LA might protect Aβ-intoxicated C6 glioma cells by alleviating oxidative damage, providing a new treatment strategy for neurodegenerative diseases.

show abstract

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Cited by 21 publications

References 30 publications

Diabetic neuropathic pain: Physiopathology and treatment

Diabetic neuropathic pain: Physiopathology and treatment

Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

Effects and mechanism of lipoic acid on beta-amyloid-intoxicated C6 glioma cells

Contact Info

Product

Resources

About